|
|
Tanya Hansotia, Adriano Maida, Grace Flock, Yuichiro Yamada, Katsushi Tsukiyama, Yutaka Seino, Daniel. J. Drucker
J Clin Invest. 2007;
117(1):143
doi:10.1172/JCI25483
Abstract |
Full text
| PDF
| Supplemental material

T
he incretin hormones glucagon-like peptide–1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) control glucose homeostasis through well-defined actions on the islet β cell via stimulation of insulin secretion and preservation and expansion of β cell mass. We examined the importance of endogenous incretin receptors for control of glucose homeostasis through analysis of Glp1r–/–, Gipr–/–, and double incretin receptor knockout (DIRKO) mice fed a high-fat (HF) diet. DIRKO mice failed to upregulate levels of plasma insulin, pancreatic insulin mRNA transcripts, and insulin content following several months of HF feeding. Both single incretin receptor knockout and DIRKO mice exhibited resistance to diet-induced obesity, preservation of insulin sensitivity, and increased energy expenditure associated with increased locomotor activity. Moreover, plasma levels of plasminogen activator inhibitor–1 and resistin failed to increase significantly in DIRKO mice after HF feeding, and the GIP receptor agonist [D-Ala2]GIP, but not the GLP-1 receptor agonist exendin-4, increased the levels of plasma resistin in studies of both acute and chronic administration. These findings extend our understanding of how endogenous incretin circuits regulate glucose homeostasis independent of the β cell via control of adipokine secretion and energy expenditure.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(52)
| Title and authors |
Publication |
Year |
Evaluation of the long-term effects of gastric inhibitory polypeptide–ovalbumin conjugates on insulin resistance, metabolic dysfunction, energy balance and cognition in high-fat-fed mice
Nigel Irwin, Ian A. Montgomery, Peter R. Flatt
|
Br J Nutr
|
2012 |
Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis
Safina Ali, Benjamin J. Lamont, Maureen J. Charron, Daniel J. Drucker
|
J. Clin. Invest.
|
2011 |
Hypothalamic control of energy and glucose metabolism
Stephanie Sisley, Darleen Sandoval
|
Rev Endocr Metab Disord
|
2011 |
The Metabolic Syndrome
Ulf Smith, Xiaolin Yang
|
The Metabolic Syndrome
|
2011 |
Glucose-dependent insulinotropic polypeptide: from pathophysiology to therapeutic opportunities in obesity-associated disorders
E. Paschetta, M. Hvalryg, G. Musso
|
Obesity Reviews
|
2011 |
GLP-1 and energy balance: an integrated model of short-term and long-term control
Jason G. Barrera, Darleen A. Sandoval, David A. D'Alessio, Randy J. Seeley
|
Nat Rev Endocrinol
|
2011 |
Gastrojejunal Stoma Diameter Predicts Weight Regain After Roux-en-Y Gastric Bypass
Barham K. Abu Dayyeh, David B. Lautz, Christopher C. Thompson
|
Clinical Gastroenterology and Hepatology
|
2011 |
Medical Therapy for Obesity
Barham K. Abu Dayyeh, Lee M. Kaplan
|
Gastrointestinal Endoscopy Clinics of North America
|
2011 |
Sub-chronic administration of stable GIP analog in mice decreases serum LPL activity and body weight
Ewa Szalowska, Kees Meijer, Niels Kloosterhuis, Farhad Razaee, Marion Priebe, Roel J. Vonk
|
Peptides
|
2011 |
Glucagon-like peptide-1(9-36)amide metabolite inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice
E. Tomas, J. A. Wood, V. Stanojevic, J. F. Habener
|
Diabetes, Obesity and Metabolism
|
2011 |
|